Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
ZSTK474 is a triazine derivative that acts as an inhibitor of class I phosphatidylinositol 3-kinase (PI3K) isoforms (IC50s = 17, 53, and 6 nM for p110β, -γ, and -δ, respectively).1 It is selective for PI3K, as it has negligible activity against 139 other kinases when tested at 30 µM.1 ZSTK474 is orally bioavailable and shows strong antitumor activity against human cancer xenografts in mice.1 The efficacy of ZSTK474 against certain cancer cells and tumors can be enhanced by combination therapy.2,3
WARNING This product is not for human or veterinary use.
1. Antitumor activity of ZSTK474, a novel phosphatidylinositol 3-
2. Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-
3. Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells. J. Cell. Mol. Med. 19(9), 2244-2252 (2015).